Mab’s pipeline pivot had a sting in the tail. Weeks after shifting its focus, the biotech said Wednesday that it has reduced ...

Uliledlimab is an antibody designed to target CD73. The development pause will also allow I-Mab to allow data from an ongoing China-only randomised study conducted by its partner TJ Biopharma ...

A second asset is AB680 (quemliclustat), a small molecule CD73 antibody running a phase 3 trial in pancreatic cancer. There’s a third molecule, Etrumadenant, and two more, Casdatifan and ...

I-MAB completed a workforce reduction as part of a Realignment Plan aimed at optimizing its operations following the pipeline reprioritization. The company reduced its workforce by approximately 27% ...

Uliledlimab (TJ004309) is an antibody designed to target CD73, the rate-limiting enzyme critical for adenosine-driven immunosuppression in the tumor microenvironment. I-Mab owns worldwide rights ...

Cidara will also participate in one-on-one investor meetings during this event. Investors interested in meeting with Cidara at the conference should contact their Guggenheim representative directly.

CD39-Targeted Therapies Near Key Milestones, First Approval Projected by 2029Dublin, Jan. 28, 2025 (GLOBE NEWSWIRE) -- The "CD39 Targeted Therapies Clinical Trials, Therapeutic Approaches & Market ...